Citations

Mayo Clinic

Showing 10 of 108523 citations.

A Unique Case of Bilateral Recurrent Sphenoid Sinus Cerebrospinal Fluid Leaks
Carlson, Matthew L. , O’Brien, Erin K. , Marston, Alexander P, Van Gompel, Jamie J, O'Brien, Erin K., Marston, Alexander P. , Gompel, Jamie J. Van , O'Brien, Erin K

Annals of Otology, Rhinology & Laryngology | February 5, 2015 | Volume: 124 | Issue: 8 | Pages: 593-597

10.1177/0003489415570936 | PMID 25653256 Get It

Objectives: This case presents a previously undescribed clinical scenario of spontaneous cerebrospinal fluid (CSF) leaks secondary to a lateral sphenoid sinus recess skull base dehiscence and contralateral Sternberg’s canal. This case report aims to characterize the presentation and successful management of these lesions. Methods: The electronic medical record was used to collect information pertaining to the patient’s clinical history. Results: The patient was a middle-aged, obese female with persistent clear rhinorrhea as her only presenting symptom. Neuroradiologic studies localized the defect to the lateral sphenoid sinus recess. CSF opening pressures were within normal limits, but radiographic findings were consistent with elevated intracranial pressure. After an endoscopic transnasal transsphenoidal approach failed to resolve the CSF leak, a transpterygoid approach facilitated CSF leak resolution. The patient then did well for the following 2 years, but later developed a CSF leak through a contralateral Sternberg’s canal. An endoscopic suprapterygoid procedure and ventriculoperitoneal shunt placement led to CSF leak resolution. Conclusion: This case demonstrates one of the only published examples of a sphenoid sinus CSF leak secondary to Sternberg’s canal as it was originally described in the literature. Wide endoscopic surgical exposure and intracranial pressure management ultimately led to CSF leak resolution.
Soft Tissue Coverage of the Mangled Upper Extremity
Ng, Zhi Yang , Salgado, Christopher J. , Moran, Steven L. , Chim, Harvey

Seminars in Plastic Surgery | February 4, 2015 | Volume: 29 | Issue: 01 | Pages: 048-054

10.1055/s-0035-1544170 | PMID 25685103 Get It

Complex Upper Extremity Reconstruction
Moran, Steven L. , Askari, Morad

Seminars in Plastic Surgery | February 4, 2015 | Volume: 29 | Issue: 01 | Pages: 003-004

10.1055/s-0035-1544164 | PMID 25685097 Get It

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Shapiro, Geoffrey I. , Bell‐McGuinn, Katherine M., Molina, Julian R. , Bendell, Johanna C. , Spicer, James , Kwak, Eunice L., Pandya, Susan , Millham, Robert, Borzillo, Gary , Pierce, Kristen J. , Han, Lixin, Houk, Brett E. , Gallo, Jorge D. , Alsina, María , Braña, Irene , Tabernero, Josep , Tabernero, Josep , Shapiro, Geoffrey I

Clinical Cancer Research | February 4, 2015 | Volume: 21 | Issue: 8 | Pages: 1888-1895

10.1158/1078-0432.ccr-14-1306 | PMID 25652454 Get It

Abstract Purpose: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors. Experimental Design: Part 1 of this open-label phase I study was designed to estimate the maximum-tolerated dose (MTD) in patients with nonselected solid tumors, using a modified continual reassessment method to guide dose escalation. Objectives of part 2 were MTD confirmation and assessment of preliminary activity in patients with selected tumor types and PI3K pathway dysregulation. Results: Seventy-seven of the 78 enrolled patients received treatment. The MTD for PF-05212384, administered intravenously once weekly, was estimated to be 154 mg. The most common treatment-related adverse events (AE) were mucosal inflammation/stomatitis (58.4%), nausea (42.9%), hyperglycemia (26%), decreased appetite (24.7%), fatigue (24.7%), and vomiting (24.7%). The majority of patients treated at the MTD experienced only grade 1 treatment-related AEs. Grade 3 treatment-related AEs occurred in 23.8% of patients at the MTD. No treatment-related grade 4–5 AEs were reported at any dose level. Antitumor activity was noted in this heavily pretreated patient population, with two partial responses (PR) and an unconfirmed PR. Eight patients had long-lasting stable disease (>6 months). Pharmacokinetic analyses showed a biphasic concentration–time profile for PF-05212384 (half-life, 30–37 hours after multiple dosing). PF-05212384 inhibited downstream effectors of the PI3K pathway in paired tumor biopsies. Conclusions: These findings demonstrate the manageable safety profile and antitumor activity of the PI3K/mTOR inhibitor PF-05212384, supporting further clinical development for patients with advanced solid malignancies. Clin Cancer Res; 21(8); 1888–95. ©2015 AACR.
New Options for Vascularized Bone Reconstruction in the Upper Extremity
Wagner, Eric R. , Nanos, George P., Moran, Steven L. , Wyles, Cody C. , Houdek, Matthew T. , Wagner, Eric R

Seminars in Plastic Surgery | February 4, 2015 | Volume: 29 | Issue: 01 | Pages: 020-029

10.1055/s-0035-1544167 | PMID 25685100 Get It

Clinical thinking in psychiatry
Wells, Lloyd A.

Journal of Evaluation in Clinical Practice | February 4, 2015 | Volume: 21 | Issue: 3 | Pages: 514-517

10.1111/jep.12324 | PMID 25653010 Get It

AbstractI discuss the lack of precision in the term ‘clinical reasoning’ and its relationship to evidence‐based medicine and critical thinking. I examine critical thinking skills, their underemphasis in medical education and successful attempts to remediate them. Evidence‐based medicine (and evidence‐based psychiatry) offer much but are hampered by the ubiquity and flaws of meta‐analysis. I explore views of evidence‐based medicine among psychiatry residents, as well as capacity for critical thinking in residents before and after a course in philosophy. I discuss decision making by experienced doctors and suggest possible futures of this issue.
Sex differences in elite swimming with advanced age are less than marathon running
Senefeld, Jonathon W. , Joyner, Michael J. , Stevens, Alyssa , Hunter, Sandra K. , Hunter, Sandra K , Joyner, Michael J , Senefeld, Jonathon W

Scandinavian Journal of Medicine & Science in Sports | February 4, 2015 | Volume: 26 | Issue: 1 | Pages: 17-28

10.1111/sms.12412 | PMID 25648250 Get It

The sex difference in marathon performance increases with finishing place and age of the runner but whether this occurs among swimmers is unknown. The purpose was to compare sex differences in swimming velocity across world record place (1st–10th), age group (25–89 years), and event distance. We also compared sex differences between freestyle swimming and marathon running. The world's top 10 swimming times of both sexes for World Championship freestyle stroke, backstroke, breaststroke, and butterfly events and the world's top 10 marathon times in 5‐year age groups were obtained. Men were faster than women for freestyle (12.4 ± 4.2%), backstroke (12.8 ± 3.0%), and breaststroke (14.5 ± 3.2%), with the greatest sex differences for butterfly (16.7 ± 5.5%). The sex difference in swimming velocity increased across world record place for freestyle (P < 0.001), breaststroke, and butterfly for all age groups and distances (P < 0.001) because of a greater relative drop‐off between first and 10th place for women. The sex difference in marathon running increased with the world record place and the sex difference for marathon running was greater than for swimming (P < 0.001). The sex difference in swimming increased with world record place and age, but was less than for marathon running. Collectively, these results suggest more depth in women's swimming than marathon running.
Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women
Tillmans, Lori S. , Vierkant, Robert A. , Wang, Alice H., Samadder, N. Jewel , Lynch, Charles F. , Anderson, Kristin E. , French, Amy J. , Haile, Robert W. , Harnack, Lisa , Potter, John D. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Limburg, Paul J. , Slager, Susan L. , Cerhan, James R. , Vierkant, Robert A , Haile, Robert W , Potter, John D

Cancer Epidemiology, Biomarkers & Prevention | February 4, 2015 | Volume: 24 | Issue: 4 | Pages: 713-719

10.1158/1055-9965.epi-14-0756 | PMID 25650184 Get It

Abstract Background: Cigarette smoking (smoking), hormone therapy (MHT), and folate intake (folate) are each thought to influence colorectal cancer risk, but the underlying molecular mechanisms remain incompletely defined. Expression of estrogen receptor β (ESR2) has been associated with colorectal cancer stage and survival. Methods: In this prospective cohort study, we examined smoking, MHT, and folate-associated colorectal cancer risks by ESR2 protein expression level among participants in the Iowa Women's Health Study (IWHS). Self-reported exposure variables were assessed at baseline. Archived, paraffin-embedded colorectal cancer tissue specimens were collected and evaluated for ESR2 protein expression by IHC. Multivariate Cox regression models were fit to estimate relative risks (RR) and 95% confidence intervals (CI) for associations between smoking, MHT, or folate and ESR2-defined colorectal cancer subtypes. Results: Informative environmental exposure and protein expression data were available for 491 incident colorectal cancer cases. Positive associations between ESR2-low and -high tumors and several smoking-related variables were noted, most prominently with average number of cigarettes per day (RR, 4.24; 95% CI, 1.81–9.91 for ESR2-low and RR, 2.15; 95% CI, 1.05–4.41 for ESR2-high for ≥40 cigarettes compared with nonsmokers). For MHT, a statistically significant association with ESR2-low tumors was observed with longer duration of exposure (RR, 0.54; 95% CI, 0.26–1.13 for &gt;5 years compared with never use). No associations were found for folate. Conclusions: In this study, smoking and MHT were associated with ESR2 expression patterns. Impact: These data support possible heterogeneous effects from smoking and MHT on ERβ-related pathways of colorectal carcinogenesis in older women. Cancer Epidemiol Biomarkers Prev; 24(4); 713–9. ©2015 AACR.
Cognitive profile of LRRK2‐related Parkinson's disease
Srivatsal, Sindhu, Leverenz, James B. , Uitti, Ryan J. , Trojanowski, John Q. , Quinn, Joseph F. , Chung, Kathryn A. , Peterson, Amie, Wood‐Siverio, Cathy, Goldman, Jennifer G. , Stebbins, Glenn T. , Bernard, Bryan, Ritz, Beate , Rausch, Rebecca , Revilla, Fredy J., Devoto, Johnna, Dawson, Ted M. , Albert, Marilyn S. , Mata, Ignácio F. , Hu, Shu‐Ching , Montine, Kathleen S. , Johnson, Catherine O., Montine, Thomas J. , Edwards, Karen L. , Cholerton, Brenna , Wszołek, Zbigniew K. , Dickson, Dennis W. , Weintraub, Daniel , Deerlin, Vivianna M. Van , Factor, Stewart Alan , Espay, Alberto J. , Rosenthal, Liana S. , Zhang, Jing , Zabetian, Cyrus P. , Goldman, Jennifer G , Leverenz, James B , Quinn, Joseph F

Movement Disorders | February 4, 2015 | Volume: 30 | Issue: 5 | Pages: 728-733

10.1002/mds.26161 | PMID 25650144 Get It

AbstractBackgroundIncreasing evidence suggests that genetic factors play a role in the variability associated with cognitive performance in Parkinson's disease (PD). Mutations in the LRRK2 gene are the most common cause of monogenic PD; however, the cognitive profile of LRRK2‐related PD is not well‐characterized.MethodsA cohort of 1,447 PD patients enrolled in the PD Cognitive Genetics Consortium was screened for LRRK2 mutations and completed detailed cognitive testing. Associations between mutation carrier status and cognitive test scores were assessed using linear regression models.ResultsLRRK2 mutation carriers (n = 29) demonstrated better performance on the Mini Mental State Examination (P = 0.03) and the Letter‐Number Sequencing Test (P = 0.005). A smaller proportion of LRRK2 carriers were demented (P = 0.03).ConclusionsOur cross‐sectional study demonstrates better performance on certain cognitive tests, as well as lower rates of dementia in LRRK2‐related PD. Future longitudinal studies are needed to determine whether LRRK2 mutation carriers exhibit slower cognitive decline. © 2015 International Parkinson and Movement Disorder Society
Diastolic Mitral Regurgitation in a Patient With Complex Native Mitral and Aortic Valve Endocarditis
Pulido, Juan N. , Lynch, James J. , Mauermann, William J., Rehfeldt, Kent H., Michelena, Héctor I.

Seminars in Cardiothoracic and Vascular Anesthesia | February 3, 2015 | Volume: 20 | Issue: 1 | Pages: 100-103

10.1177/1089253215570063 | PMID 25648613 Get It

Diastolic mitral valve regurgitation is a rare phenomenon described in patients with atrioventricular conduction abnormalities, severe left ventricular systolic or diastolic dysfunction with regional wall motion dyssynchrony, or severe acute aortic valve regurgitation. The presence of diastolic mitral valve regurgitation in acute aortic regurgitation due to endocarditis suggests critical severity requiring urgent surgical valve replacement. We describe a case of diastolic mitral regurgitation in the setting of complex native mitral-aortic valve endocarditis in a patient in normal sinus rhythm and review the etiologic mechanisms of this phenomenon, echocardiographic assessment, and therapeutic implications for hemodynamic management.